WARF: P06361US

Antibacterial Agents Using Small Molecule Macroarrays


Helen Blackwell, Matthew Bowman, Jennifer Campbell Butler, Joseph Stringer

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing novel antibiotic compositions that exhibit potent antibacterial activity against MRSA and potentially other Gram-positive pathogens.
OVERVIEWStaphylococcus aureus is a Gram-positive bacterium responsible for many infectious diseases, including toxic shock syndrome, food poisoning and topical skin infections. Although S. aureus is usually amenable to antibiotic treatment, a highly virulent strain, methicillin resistant S. aureus (MRSA), is a leading cause of hospital-acquired infections in the United States.
THE INVENTIONUW-Madison researchers have developed novel chemical agents that exhibit potent antibacterial activity against MRSA and potentially other Gram-positive bacterial pathogens. To identify these compounds, the inventors developed a versatile discovery platform that couples array technology with high throughput screening techniques to simply and rapidly synthesize small molecules and screen them for antibacterial activity.
  • Treatment of bacterial infections, including infections with antibiotic-resistant bacteria such as MRSA
  • Provides novel antibiotic compositions
  • Platform enables facile synthesis, screening and lead optimization of compounds.
  • Compounds can be identified without labor-intensive and time-consuming deconvolution steps.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.